Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-213 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARGX-213 | EXPERIMENTAL | Participants receiving the experimental drug |
| Placebo | PLACEBO_COMPARATOR | Participants receiving placebo |
| Name | Type | Description |
|---|---|---|
| ARGX-213 | BIOLOGICAL | Intravenous or subcutaneous administrations of ARGX-213 |
| Placebo | OTHER | Intravenous or subcutaneous administrations of placebo |
Inclusion Criteria: * Is at least the local legal age of consent for clinical studies and is aged 18 to 65 years, inclusive, when signing the ICF * Is a female of nonchild bearing potential (either postmenopausal or surgically sterilized) or a male * Has a body weight between 50 and 100 kg and a BM...
ARGX-213 is an investigational monoclonal antibody developed by argenx SE. It is in Phase 1 clinical development, with one completed Phase 1 trial conducted in healthy adult volunteers. No approved indication has been announced for ARGX-213.
ARGX-213 targets FcRn, the neonatal Fc receptor. FcRn is a protein that recycles immunoglobulin G antibodies and extends their circulation time in the body. By binding FcRn, ARGX-213 is designed to interact with this recycling pathway.
ARGX-213 is developed by argenx SE, the Belgian immunology company listed on Nasdaq under the ticker ARGX. Argenx is the sponsor of the clinical program evaluating ARGX-213.
ARGX-213 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The Phase 1 program has completed one trial, and no active trials are currently listed.
ARGX-213 has been studied in one Phase 1 trial, NCT06968338, titled A Study to Assess the Safety of ARGX-213 in Healthy Volunteers. That trial was completed, enrolled 88 participants, was randomized, double blind, and placebo controlled, and was conducted in Canada.